Hiroshi Nokihara

Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

Toyoaki Hida, Hiroshi Nokihara, Masashi Kondo et al. · The Lancet · 2017 · 912 citations

Medicine, Oncology, Pharmacology +14

Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non–Small-Cell Lung Cancer

Toshimi Takano, Yuichiro Ohe, Hiromi Sakamoto et al. · Journal of Clinical Oncology · 2005 · 708 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020 · 687 citations · Full text

Medicine, Oncology, Pharmacology +14

Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial

Toshiaki Takahashi, Takeharu Yamanaka, Takashi Seto et al. · The Lancet Oncology · 2017 · 533 citations

Medicine, Oncology, Radiation Oncology +11

The Clinical Relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 Network in Chemoresistant Non-small-cell Lung Cancer

Yu Fujita, Shigehiro Yagishita, Keitaro Hagiwara et al. · Molecular Therapy · 2015 · 262 citations · Full text

Medicine, Cancer Biology, Oncology +17